Pentixapharm Holding AG (ETR:PTP)

Germany · Delayed Price · Currency is EUR

2.150

-0.020 (-0.92%)

At close: Jun 19, 2026

-12.60% (1Y)

Market Cap	53.28M -11.2%
Revenue (ttm)	397.00K -58.5%
Net Income	-15.68M
EPS	-0.64
Shares Out	24.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,092
Open	2.200
Previous Close	2.170
Day's Range	2.150 - 2.200
52-Week Range	1.300 - 3.700
Beta	n/a
Analysts	Strong Buy
Price Target	11.72 (+445.12%)
Earnings Date	Aug 6, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Employees 36

Stock Exchange Deutsche Börse Xetra

Ticker Symbol PTP

Full Company Profile

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -74.37% compared to the previous year's 2.05 million. Losses were -16.51 million, 26.4% more than in 2024.

Financial Statements